Table 1 Analysis of personalized cancer-specific rearranged sequences in gastric cancer patients

From: Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer

ID

Sex

Age

Recurrence status

Stage (TNM)

Rearranged sites in WG-NGS

Primers designed for PCR sites

Cancer-specific PCR

Confirmed by Sanger sequencing

Final validated sites

PreOp ctDNA

PostOp ctDNA

Lead time (months)

GC1

M

68

R

IIIA (T3N2M0),

48

12

7

4

4

–

–

Ā 

GC4

M

67

R

IIIC (T4aN3bM0)

44

7

3

3

3

+

+

9.4

GC6

M

64

R

IIIB (T3N3aM0)

3

3

3

3

3

āˆ’

āˆ’

Ā 

GC7

M

57

R

IIIB (T4aN2M0)

3

3

3

1

1

āˆ’

Ā Ā 

GC8

M

53

R

IIIC (T4bN3aM0)

8

6

4

3

2

+

+

āˆ’1.4

GC9

M

44

R

GIST (T4N0M0)

8

8

3

3

3

+

+

5.0

GC10

M

73

R

IIIB (T4aN2M0)

31

5

3

3

3

āˆ’

āˆ’

Ā 

GC11

M

70

R

IIIB (T3N3aM0)

90

12

6

5

5

+

+

5.6

GC12

M

71

R

IIIC (T4aN3aM0)

3

3

3

2

2

āˆ’

āˆ’

Ā 

GC14

M

53

R

IIIB (T3N3bM0)

25

11

4

2

2

āˆ’

+

0.7

GC15

M

42

R

IIIC (T4bN3aM0)

7

7

5

3

2

+

+

3.1

GC17

M

71

R

IV (T4aN3bP1)

16

12

8

5

5

+

+

a

GC18

M

41

R

IIB (T3N1M0),

6

5

4

2

2

āˆ’

āˆ’

Ā 

GC21

M

77

R

IIIC (T4aN3aM0)

40

13

6

6

5

āˆ’

āˆ’

Ā 

GC22

M

49

R

IV (T4aN3bP1)

23

9

3

3

3

+

+

a

GC31

M

54

N

IIA (T3N0M0),

6

5

4

3

3

+

āˆ’

Ā 

GC32

M

70

R

IIIC (T4bN2M0)

11

8

8

8

8

+

āˆ’

Ā 

GC33

M

44

N

IIIC (T4bN3bM0)

6

6

6

6

6

+

āˆ’

Ā 

GC34

M

63

N

IIIC (T4aN3aM0)

3

3

1

1

1

+

āˆ’

Ā 

CG35b

M

60

N

IIA (T3N0M0)

0

0

0

0

0

Ā Ā Ā 

GC2b

F

62

R

IIB (T3N1M0)

0

0

0

0

0

Ā Ā Ā 

GC3b

M

64

R

IIIB (T4aN2M0)

0

0

0

0

0

Ā Ā Ā 

GC5b

F

72

R

IIIC (T4aN3bM0)

0

0

0

0

0

Ā Ā Ā 

GC13b

F

73

R

IIIA (T3N2M0)

0

0

0

0

0

Ā Ā Ā 

GC23b

M

60

R

IIIA (T3N2M0)

3

3

0

0

0

Ā Ā Ā 

Total

Ā Ā Ā Ā 

384

141

84

66

63

Ā Ā Ā 
  1. R recurrence, N nonrecurrence, PreOp preoperative, PostOp postoperative
  2. āˆ’ negative ctDNA,+ positive ctDNA
  3. aCases of positive peritoneal seeding
  4. bNo cancer-specific rearrangement was found in WGS, and no ctDNA monitoring was performed